9.77
-0.37
(-3.68%)
At close: January 31 at 9:34:10 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
43,086.00
36,275.00
52,121.00
33,053.00
57,994.00
Operating Expense
580,794.00
551,566.00
510,285.00
300,903.00
194,577.00
Operating Income
-537,708.00
-515,291.00
-458,164.00
-267,850.00
-136,583.00
Net Non Operating Interest Income Expense
49,635.00
49,832.00
8,542.00
1,283.00
2,352.00
Other Income Expense
-34,211.00
-15,733.00
-24,564.00
-1,325.00
--
Pretax Income
-522,284.00
-481,192.00
-474,186.00
-267,892.00
-134,231.00
Net Income Common Stockholders
-522,284.00
-481,192.00
-474,186.00
-267,892.00
-134,231.00
Diluted NI Available to Com Stockholders
-522,284.00
-481,192.00
-474,186.00
-267,892.00
-134,231.00
Basic EPS
-5.45
-5.42
-6.16
-3.78
-2.40
Diluted EPS
-5.45
-5.42
-6.16
-3.78
-2.40
Basic Average Shares
95,998.50
88,770.00
76,972.00
70,894.00
55,987.00
Diluted Average Shares
95,998.50
88,770.00
76,972.00
70,894.00
55,987.00
Total Operating Income as Reported
-537,708.00
-515,291.00
-458,164.00
-267,850.00
-136,583.00
Total Expenses
580,794.00
551,566.00
510,285.00
300,903.00
194,577.00
Net Income from Continuing & Discontinued Operation
-522,284.00
-481,192.00
-474,186.00
-267,892.00
-134,231.00
Normalized Income
-492,801.00
-481,092.00
-460,701.00
-267,892.00
-134,231.00
Interest Income
49,635.00
49,832.00
8,542.00
1,283.00
2,352.00
Net Interest Income
49,635.00
49,832.00
8,542.00
1,283.00
2,352.00
EBIT
-537,708.00
-515,291.00
-458,164.00
-267,850.00
-136,583.00
EBITDA
-527,523.00
-506,315.00
-450,592.00
-260,959.00
-130,272.00
Reconciled Depreciation
10,185.00
8,976.00
7,572.00
6,891.00
6,311.00
Net Income from Continuing Operation Net Minority Interest
-522,284.00
-481,192.00
-474,186.00
-267,892.00
-134,231.00
Total Unusual Items Excluding Goodwill
-29,483.00
-100.00
-13,485.00
--
--
Total Unusual Items
-29,483.00
-100.00
-13,485.00
--
--
Normalized EBITDA
-498,040.00
-506,215.00
-437,107.00
-260,959.00
-130,272.00
12/31/2020 - 8/28/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
FYB.MU Formycon AG
54.70
+1.11%
1U5.SG Wave Life Sciences Ltd.
11.10
-3.48%
63E.MU Onward Medical NV
6.34
-6.49%
63E.BE Onward Medical NV
6.38
+0.31%
VVY.AS Vivoryon Therapeutics N.V.
2.0000
-0.50%
FYB.DE Formycon AG
53.60
-0.92%
ONWD.BR Onward Medical N.V.
6.36
+0.95%
BMEA Biomea Fusion, Inc.
4.1800
-1.65%
DNLI Denali Therapeutics Inc.
23.30
-1.19%
TERN Terns Pharmaceuticals, Inc.
4.4600
-3.88%